This is the first update to the original CTS communication distributed on July 6th. As previously communicated, all CTS healthcare partners will remain on the Grifols ZIKV clinical trial until at least the end of October 2018, which coincides with the end of the WNV season.
Check out the Communication page for the complete details on the NAT ZIKV test update or by clicking the link: Communications
As an organization dedicated to the safety of the world’s blood and plasma supply, Creative Testing...
We are very excited to launch our new website! Please take a few moments to click around and explore...
In 2016, the Procleix Panther instrument was introduced by Grifols in support of automated NAT ZIKA ...
On July 6, 2018 the FDA released an industry guidance document for transitioning from individual to ...
Josh Moon has been appointed Chief Operating Officer (COO) at Creative Testing Solutions (CTS), effe...
On April 29, 2019, CTS will begin performing Donor-Screen HLA® Class I and II testing on the Str...